Evidence map›Paper›PMID 19810623›Full record

SynthesisThe journal of spinal cord medicine2009

Bisphosphonate use in acute and chronic spinal cord injury: a systematic review.

Julia E Bryson, Margaret L Gourlay

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The journal of spinal cord medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Osteoporosis after spinal cord injury: aetiology, effects and therapeutic approaches.Journal of musculoskeletal & neuronal interactions · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Treatment with hydrogen sulfide attenuates sublesional skeletal deterioration following motor complete spinal cord injury in rats.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017
    Article
  12. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
    Observational
  13. Review
  14. Observational
  15. Bone loss in a new rodent model combining spinal cord injury and cast immobilization.Journal of musculoskeletal & neuronal interactions · 2014
    Article
  16. Bisphosphonate treatment for children with disabling conditions.PM & R : the journal of injury, function, and rehabilitation · 2014
    Review
  17. Bisphosphonate therapy in pediatric patients.Journal of diabetes and metabolic disorders · 2014
    Review
  18. Spinal Cord Injury and Osteoporosis: Causes, Mechanisms, and Rehabilitation Strategies.International journal of physical medicine & rehabilitation · 2013
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Julia E BrysonDepartment of Physical Medicine and Rehabilitation, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina 27517, USA. jb@juliabryson.com
Margaret L Gourlay

Funding

Selective screening for osteoporosis in younger postmenopausal womenK23RR024685 · NCRR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GOURLAY, MARGARET L · 2007 to 2011
$662k
NCRR NIH HHS K23 RR024685NCRR NIH HHS K23RR024685
6 · The paper itself

Abstract

BACKGROUND/

objectiveBone density loss occurs rapidly after traumatic spinal cord injury (SCI) and is associated with low-energy fractures below the level of injury, commonly occurring around the knee. Bisphosphonates have been tested as potential agents to prevent bone loss after SCI, but no guidelines exist for clinical use of bisphosphonates in these patients. The objective of this study was to systematically review and evaluate evidence quality in studies of bisphosphonate use in patients with post-treatment follow-up of sublesional bone mineral density.

methodsLiterature search in MEDLINE/PubMed and ISI database using key words bisphosphonates, spinal cord injury, quadriplegia, paraplegia, and tetraplegia.

resultsThe search identified 6 experimental studies and 1 quasi-experimental study of bisphosphonate therapy in patients with acute and chronic SCI. The studies were small and of fair or poor quality, and none included fracture outcomes. Mild attenuation of bone density loss with acute administration of bisphosphonates after SCI was found at some measurement sites but was not always maintained during follow-up.

conclusionsData were insufficient to recommend routine use of bisphosphonates for fracture prevention in these patients. Current studies are limited by heterogeneity of patient populations and outcome measures. Uniform bone density measurement sites with rigorous quality control and compliance monitoring are needed to improve reliability of outcomes. Future studies should address specific populations (acute or chronic SCI) and should assess fracture outcomes.

Indexed as

Bone Density Conservation AgentsDiphosphonatesHumansMEDLINEPubMedSpinal Cord InjuriesBone Density Conservation AgentsDiphosphonates

Identifiers

PMID19810623
PMCPMC2718822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.